Al18F-NOTA-LM3

Al18F-NOTA-LM3 is a radiopharmaceutical imaging agent developed by Peking Union Medical College Hospital for the diagnosis and evaluation of pheochromocytoma and paraganglioma (PPGL). The agent consists of the somatostatin receptor (SSTR) antagonist peptide LM3, which is conjugated to the chelator NOTA (1,4,7-triazacyclononane-1,4,7-triacetic acid) and radiolabeled with aluminum fluoride-18 (Al18F). As an SSTR antagonist, LM3 binds to a broader range of receptor conformations compared to traditional agonists like DOTATATE, potentially resulting in higher tumor uptake and improved diagnostic sensitivity for both primary tumors and various metastatic lesions, including those in the bone, liver, and lungs. The use of the 18F isotope offers significant logistical and imaging advantages over 68Ga-labeled probes, including a longer half-life (approximately 110 minutes) and lower positron energy, which leads to superior spatial resolution in PET/CT scans and facilitates centralized production.

Other names

18F-AlF-NOTA-LM3[18F]AlF-NOTA-LM3